文献速递流行病学与生物统计新药、器械与细胞基因治疗研发

50岁以上成人天然与合成大麻素的安全性与耐受性:系统综述与荟萃分析

Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis.
PubMed 文献 · PLoS Med · 2021-03-29

该系统综述与荟萃分析纳入46项随机对照试验、6216例平均年龄58.6±7.5岁的患者,评估大麻素类药物在≥50岁成人中的安全性与耐受性。含THC的大麻素类药物显著增加全因及治疗相关不良事件发生率,但严重不良事件和死亡风险未显著增加;单纯CBD未增加全因不良事件。总体认为大麻素类药物在老年人中安全可接受,但THC:CBD组合的耐受性可能较差。

要点

  • 含THC的大麻素类药物显著增加全因和治疗相关不良事件,但未显著增加严重不良事件或死亡。
  • 单纯CBD未增加全因不良事件发生率。
  • THC:CBD组合显著增加不良事件相关退出风险,且退出风险与THC剂量相关。

核心结论

  • 含THC的大麻素类药物与不良事件增加相关,但大麻素类药物在老年人中总体安全可接受。
  • THC:CBD组合在所用剂量范围内可接受性可能较低,在65或75岁以上成人中耐受性可能不同。

研究设计与样本

  • 纳入平均年龄≥50岁、量化不良事件的大麻素类药物随机对照试验,共46项RCT、6216例患者(平均年龄58.6±7.5岁,51%男性),其中3469例接受大麻素类药物。
  • 采用GRADE标准评估研究质量,遵循PRISMA指南,两名评价员独立完成各阶段,尽可能采用随机效应荟萃分析。

主要发现

  • 与对照相比,单纯THC的全因不良事件IRR为1.42(95% CI 1.12至1.78),治疗相关不良事件IRR为1.60(95% CI 1.26至2.04)。
  • THC:CBD组合的全因不良事件IRR为1.58(95% CI 1.26至1.98),治疗相关不良事件IRR为1.70(95% CI 1.24至2.33)。
  • 含THC的大麻素类药物未显著增加严重不良事件和死亡的IRR。
  • THC:CBD组合显著增加不良事件相关退出风险(RR 1.40,95% CI 1.08至1.80),单纯THC未显著增加(RR 1.18,95% CI 0.89至1.57)。
  • 单纯CBD未增加全因不良事件(IRR 1.02,95% CI 0.90至1.16);不良事件相关退出与THC剂量显著相关(单纯THC:QM(df=1)=4.696,p=0.03;THC:CBD组合:QM(df=1)=4.554,p=0.033)。

关键数值与推荐

  • 含THC的大麻素类药物显著增加口干、头晕/头昏和嗜睡/困倦的发生率。

临床怎么用

  • 在≥50岁成人中使用含THC的大麻素类药物时,应监测全因及治疗相关不良事件,尤其是口干、头晕和嗜睡。
  • 单纯CBD未增加全因不良事件,可作为需要考虑不良事件风险时的选择之一。
  • 使用THC:CBD组合时需关注耐受性和退出风险,并注意THC剂量与不良事件相关退出相关。

局限性

  • 主要分析无法完全排除年龄<50岁的数据。
  • 纳入试验存在弱点,尤其是结局报告不完整和研究间异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cannabinoid-based medicines (CBMs) are being used widely in the elderly. However, their safety and tolerability in older adults remains unclear. We aimed to conduct a systematic review and meta-analysis of safety and tolerability of CBMs in adults of age ≥50 years. METHODS AND FINDINGS: A systematic search was performed using MEDLINE, PubMed, EMBASE, CINAHL PsychInfo, Cochrane Library, and ClinicalTrials.gov (1 January 1990 to 3 October 2020). Randomised clinical trials (RCTs) of CBMs in those with mean age of ≥50 years for all indications, evaluating the safety/tolerability of CBMs where adverse events have been quantified, were included. Study quality was assessed using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) criteria and Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. Two reviewers conducted all review stages independently. Where possible, data were pooled using random-effects meta-analysis. Effect sizes were calculated as incident rate ratio (IRR) for outcome data such as adverse events (AEs), serious AEs (SAEs), and death and risk ratio (RR) for withdrawal from study and reported separately for studies using tetrahydrocannabinol (THC), THC:cannabidiol (CBD) combination, and CBD. A total of 46 RCTs were identified as suitable for inclusion of which 31 (67%) were conducted in the United Kingdom and Europe. There were 6,216 patients (mean age 58.6 ± 7.5 years; 51% male) included in the analysis, with 3,469 receiving CBMs. Compared with controls, delta-9-tetrahydrocannabinol (THC)-containing CBMs significantly increased the incidence of all-cause and treatment-related AEs: THC alone (IRR: 1.42 [95% CI, 1.12 to 1.78]) and (IRR: 1.60 [95% CI, 1.26 to 2.04]); THC:CBD combination (IRR: 1.58 [95% CI,1.26 to 1.98]) and (IRR: 1.70 [95% CI,1.24 to 2.33]), respectively. IRRs of SAEs and deaths were not significantly greater under CBMs containing THC with or without CBD. THC:CBD combination (RR: 1.40 [95% CI, 1.08 to 1.80]) but not THC alone (RR: 1.18 [95% CI, 0.89 to 1.57]) significantly increased risk of AE-related withdrawals. CBD alone did not increase the incidence of all-cause AEs (IRR: 1.02 [95% CI, 0.90 to 1.16]) or other outcomes as per qualitative synthesis. AE-related withdrawals were significantly associated with THC dose in THC only [QM (df = 1) = 4.696, p = 0.03] and THC:CBD combination treatment ([QM (df = 1) = 4.554, p = 0.033]. THC-containing CBMs significantly increased incidence of dry mouth, dizziness/light-headedness, and somnolence/drowsiness. Study limitations include inability to fully exclude data from those <50 years of age in our primary analyses as well as limitations related to weaknesses in the included trials particularly incomplete reporting of outcomes and heterogeneity in included studies. CONCLUSIONS: This pooled analysis, using data from RCTs with mean participant age ≥50 years, suggests that although THC-containing CBMs are associated with side effects, CBMs in general are safe and acceptable in older adults. However, THC:CBD combinations may be less acceptable in the dose ranges used and their tolerability may be different in adults over 65 or 75 years of age.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Velayudhan L, McGoohan K, Bhattacharyya S, et al. Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis. PLoS Med. 2021. PMID: 33780450. doi:10.1371/journal.pmed.1003524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。